Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series

Studies have shown that the bortezomib-based retreatment of patients with multiple myeloma (MM) may prolong control of the disease. The optimal duration of bortezomib-based retreatment in relapsed or refractory MM is unknown. The present retrospective study evaluated the efficacy and safety of short...

Descripción completa

Detalles Bibliográficos
Autores principales: MAO, JINGJUE, CHENG, FENG, CHEN, HENG, WANG, JING, ZHOU, XIN, JIANG, YUANQIANG, ZHU, YUANXIN, GUO, HONGFENG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964925/
https://www.ncbi.nlm.nih.gov/pubmed/24669261
http://dx.doi.org/10.3892/etm.2014.1496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964925/
https://www.ncbi.nlm.nih.gov/pubmed/24669261
http://dx.doi.org/10.3892/etm.2014.1496

Ejemplares similares